Medicare is preparing to test CBD treatments for seniors for the first time, with the details appearing in a Federal Register proposal that is scheduled for official publication on November 28 but is already available in PDF form.
The pilot program is part of a sweeping 465-page rule outlining Medicare Advantage and prescription drug program changes for 2027. The proposal notes that Medicare will evaluate CBD in real-world medical settings, analyzing safety, dosing consistency, product quality and patient outcomes.
Although the rule is broad and covers major updates to Part C and Part D, its discussion of CBD frames the pilot as an evidence-gathering initiative aimed at determining how cannabidiol fits into Medicare’s clinical and financial structure.
The Centers for Medicare & Medicaid Services (CMS) emphasizes the need for greater clarity on product standards, pointing to issues such as variable potency and inconsistent labeling in commercial CBD products. The agency suggests the pilot would focus on FDA-regulated or pharmaceutically manufactured formulations.
The move comes as Medicare continues searching for alternatives to opioid-based pain treatments, particularly for chronic conditions common among seniors. The rule indicates that CBD’s potential benefits, including pain reduction and improved quality of life, warrant direct evaluation by the program rather than relying on outside studies alone.
If finalized, the pilot would launch alongside the 2027 plan year and could shape whether CBD becomes a permanent, covered therapy for older adults. CMS is accepting public comments through January 26, 2026.
More articles from The Marijuana Herald can be found below.
